Albuminuria Reduction Study With Survodutide Treatment in Kidney Disease

NCT07206290 · Not yet recruiting

Last updated 2026-05-28

This clinical trial is testing the effects of survodutide, a new medication, on reducing albumin in the urine of adults with chronic kidney disease.

Status Not yet recruiting Approved but enrollment has not started.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 120 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2026-03 · est. completion 2027-11

What this study is testing ClinicalTrials.gov NCT07206290 ↗

Description as written by the study sponsor.

The ARTIST-CKD trial is a clinical study evaluating the effect of weekly subcutaneous administration of survodutide (3.6 mg) on kidney function in patients with chronic kidney disease (CKD) and elevated albuminuria. The primary objective is to determine whether survodutide leads to early, sustained, and clinically meaningful reductions in albuminuria, regardless of diabetes status.

Treatments tested

Survodutide (BI 456906) Drug

0.3 mg, 0.6 mg, 1.2 mg, 2.4 mg, 3.6 mg s.c. weekly
Placebo Drug

Placebo matching survodutide

Main thing measured	Change in first morning void UACR
Sponsor	University Medical Center Groningen
Conditions studied	Chronic Kidney Disease
GLP-1 drugs	survodutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07206290 ↗